Intensity Therapeutics enters collaboration with SAKK for Phase 2 breast cancer study of INT230-6

INTENSITY THERAPEUTICS, INC.

SAKK to conduct Phase 2 of INVINCIBLE-4 Study testing INT230-6 plus standard of care vs standard of care alone in neoadjuvant triple negative breast cancer in Europe.
Intensity will supply INT230-6 and provide up to approximately $3.0 million in funding for the study.
Indemnification: SAKK indemnifies Intensity for claims from its study duties; Intensity indemnifies SAKK for issues from drug manufacturing, packaging, labeling.
Term runs until final clinical study report; either party may terminate for material breach, negligible scientific value, safety, or significant recruitment delay (>12 months).

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

INTENSITY THERAPEUTICS, INC. entered into Collaboration Agreement with The Swiss Group for Cancer Research SAKK valued at funding in the amount of up to approximately $3.0 million (effective 2024-05-06).

Action: entry
Agreement: collaboration
Counterparty: The Swiss Group for Cancer Research SAKK
Value: funding in the amount of up to approximately $3.0 million
Effective: 2024-05-06

Exact text from the filing

On May 6, 2024, Intensity Therapeutics, Inc. (the “Company”) entered into a collaboration agreement (the “Collaboration Agreement”) with The Swiss Group for Cancer Research SAKK (“SAKK”).

View on SEC.gov

329 material agreements filed in the last 30 days. Browse all material agreements →

INTENSITY THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001567264-24-000013

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.